These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16936925)

  • 1. Glycolipids for natural killer T cells.
    Savage PB; Teyton L; Bendelac A
    Chem Soc Rev; 2006 Sep; 35(9):771-9. PubMed ID: 16936925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of natural killer T cells by glycolipids.
    Tupin E; Kronenberg M
    Methods Enzymol; 2006; 417():185-201. PubMed ID: 17132506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
    Florence WC; Bhat RK; Joyce S
    Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].
    Watarai H; Tashiro T; Chiba T; Taniguchi M
    Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371
    [No Abstract]   [Full Text] [Related]  

  • 6. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells.
    Liu Y; Goff RD; Zhou D; Mattner J; Sullivan BA; Khurana A; Cantu C; Ravkov EV; Ibegbu CC; Altman JD; Teyton L; Bendelac A; Savage PB
    J Immunol Methods; 2006 May; 312(1-2):34-9. PubMed ID: 16647712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control points in NKT-cell development.
    Godfrey DI; Berzins SP
    Nat Rev Immunol; 2007 Jul; 7(7):505-18. PubMed ID: 17589542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo response of invariant natural killer T cells to glycolipid antigens.
    Parekh VV; Lalani S; Van Kaer L
    Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell recognition of glycolipids presented by CD1 proteins.
    Young DC; Moody DB
    Glycobiology; 2006 Jul; 16(7):103R-112R. PubMed ID: 16597658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between carbohydrate and lipid in recognition of glycolipid antigens by natural killer T cells.
    Pei B; Vela JL; Zajonc D; Kronenberg M
    Ann N Y Acad Sci; 2012 Apr; 1253(1):68-79. PubMed ID: 22352829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
    Miyake S; Yamamura T
    Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of natural killer T cells by glycolipids.
    Anderson BL; Teyton L; Bendelac A; Savage PB
    Molecules; 2013 Dec; 18(12):15662-88. PubMed ID: 24352021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The regulatory role of natural killer T cells in the airways.
    Umetsu DT; Dekruyff RH
    Int J Biochem Cell Biol; 2010 Apr; 42(4):529-34. PubMed ID: 19897049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.
    Mallevaey T; Fontaine J; Breuilh L; Paget C; Castro-Keller A; Vendeville C; Capron M; Leite-de-Moraes M; Trottein F; Faveeuw C
    Infect Immun; 2007 May; 75(5):2171-80. PubMed ID: 17353286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKT cells: T lymphocytes with innate effector functions.
    Van Kaer L
    Curr Opin Immunol; 2007 Jun; 19(3):354-64. PubMed ID: 17428648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-Glycosphingolipids as immune modulators.
    Adar T; Ilan Y
    J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycolipids with nonreducing end alpha-mannosyl residues that have the potential to activate invariant Valpha19 NKT cells.
    Shimamura M; Huang YY; Okamoto N; Watanabe Y; Murakami Y; Kinoshita T; Hirabayashi Y; Murakata C; Ito Y; Ogawa T
    FEBS J; 2007 Jun; 274(11):2921-32. PubMed ID: 17488284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the behavior of invariant NKT cells in autoimmune diseases.
    Yamamura T; Sakuishi K; Illés Z; Miyake S
    J Neuroimmunol; 2007 Nov; 191(1-2):8-15. PubMed ID: 17905445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional, regulatory, and unconventional T cells in the immunologic response to Helicobacter pylori.
    O'Keeffe J; Moran AP
    Helicobacter; 2008 Feb; 13(1):1-19. PubMed ID: 18205661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.